689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2

• Lien Vandenberk,
• Paula Rodríguez-Otero,
• Maria-Victoria Mateos,
• Ajai Chari,
• Bhagirathbhai Dholaria,
• Deeksha Vishwamitra,
• Sheri Skerget,
• M Damiette Smit,
• Kalpana Bakshi,
• Sangmin Lee,
• Nizar Bahlis,
• Niels WCJ van de Donk,
• Raluca Verona

Affiliations

Lien Vandenberk

3Janssen Research and Development, Antwerp, Belgium

Paula Rodríguez-Otero

7Clínica Universidad de Navarra, CCUN, University of Navarra, Navarra, Pamplona, Spain

Maria-Victoria Mateos

5University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain

Ajai Chari

6Mount Sinai School of Medicine, New York, NY, USA

Bhagirathbhai Dholaria

4Vanderbilt University Medical Center, Nashville, TN, USA

Deeksha Vishwamitra

1Janssen Research and Development, Spring House, PA, USA

Sheri Skerget

1Janssen Research and Development, Spring House, PA, USA

M Damiette Smit

2Janssen Biologics B.V, Leiden, Netherlands

Kalpana Bakshi

1Janssen Research and Development, Spring House, PA, USA

Sangmin Lee

1Janssen Research and Development, Spring House, PA, USA

Nizar Bahlis

8Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada

Niels WCJ van de Donk

9Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

Raluca Verona

1Janssen Research and Development, Spring House, PA, USA